Search results for Panitumumab

Panitumumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1148-

Panitumumab, Kyinno, KB-1394

Panitumumab, Affinityimmuno, ab-131-panitumumab

Panitumumab, Abbexa, abx831106

Panitumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting EGFR, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Ruplizumab is an anti-CD40L monoclonal antibody. The binding of CD40 to its ligand, CD40L, is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells, and monocytes.

Panitumumab Antibody, Abbexa, abx376583

Panitumumab Antibody is a rabbit polyclonal antibody for the detection of Panitumumab.

Panitumumab ELISA Kit, ProteoGenix, KPTX123

Description of Panitumumab ELISA Kit Panitumumab ELISA Kit: A Comprehensive Guide Panitumumab ELISA Kit: Structure, Activity and Application Introduction Panitumumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), a protein that is overexpressed in many types of cancer. It is used as a therapeutic agent for the treatment of metastatic colorectal cancer and head and neck cancer. The Panitumumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of this important therapeutic target. Structure of Panitumumab Panitumumab is a fully humanized IgG2 monoclonal antibody, meaning that it is derived from human cells and has a structure similar to the antibodies produced by our own immune system. It is composed of two heavy chains and two light chains, each with distinct regions that contribute to its function. The variable region of Panitumumab is responsible for its specificity and binding to EGFR. This region contains six complementarity-determining regions (CDRs) that interact with specific amino acid sequences on the target protein. The constant region of the antibody is responsible for its effector functions, such as activating the immune system to attack cancer cells. Activity of Panitumumab Panitumumab binds to the extracellular domain of EGFR, preventing the binding of its natural ligands and inhibiting downstream signaling pathways. This leads to decreased cell proliferation and increased cell death in cancer cells that overexpress EGFR. In addition to its direct anti-tumor effects, Panitumumab also has immunomodulatory properties. It can activate immune cells, such as natural killer cells and macrophages, to target and destroy cancer cells. This makes it a powerful tool in the fight against cancer. Application of Panitumumab ELISA Kit The Panitumumab ELISA Kit is a valuable tool for researchers and clinicians studying EGFR and its role in cancer. It allows for the quantification of Panitumumab in various biological samples, such as serum, plasma, and tissue lysates. The kit utilizes a sandwich ELISA format, where the target antibody is captured by a specific coating antibody and then detected by a secondary antibody conjugated to an enzyme. The resulting color change is measured and correlates to the amount of Panitumumab present in the sample. This highly sensitive and specific assay can detect Panitumumab at levels as low as 0.1 ng/mL, making it a valuable tool for pharmacokinetic studies and monitoring of treatment efficacy. It can also be used to screen for potential drug interactions or to assess patient compliance with therapy. Conclusion In summary, the Panitumumab ELISA Kit is a vital tool for the detection and quantification of Panitumumab, a monoclonal antibody used in the treatment of cancer. Its structure, activity, and application make it a powerful therapeutic agent and a valuable tool for research and clinical practice. With its high sensitivity and specificity, this kit is an essential addition to any laboratory studying EGFR and its role in cancer biology.

Panitumumab ELISA Kit, Abbexa, abx395012

Panitumumab ELISA Kit is a quantitative ELISA kit for detection of Panitumumab.Panitumumab, formerly ABX-EGF, is a fully human monoclonal antibody (mAb) specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab was originally developed by Abgenix using Abgenix's XenoMouse platform technology, in which engineered mice were utilized to produce human antibodies. This methodology is based on inactivating the mouse immunoglobulin genes that are replaced by a megabase gene containing the human heavy and κ chains. The result is the generation of fully human antibodies that do not contain murine portions of the IgG molecule as chimeric antibodies do. This property avoids the formation of human antimouse antibodies, which may result in more frequent hypersensitivity reactions and shorter half-life.

Anti-Panitumumab Polyclonal Antibody, AntibodySystem, PAB86902

Panitumumab Biosimilar - Research Grade, ichor.bio, ICH4028

Detects human EGFR. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Panitumumab.

Research Grade Panitumumab (HF004036), abinScience, HF004036